Impacto potencial y análisis coste-eficacia de la profilaxis con palivizumab, en la prevención de bronquiolitis, en prematuros menores de 33 semanas de gestación

Autor: M.aB. Robles García, L. Castañón Fernández, J. Mallo Castaño, J.P. Martínez Badás, S. Lapeña López de Armentia, E. Álvaro Iglesias, B. Herrero Mendoza

Publikováno v: Anales de Pediatría, Vol 59, Iss 4, Pp 328-333 (2003)

Introducción: El virus respiratorio sincitial (VRS) es la causa principal de bronquiolitis en menores de 2 años. Recientemente se ha constatado la eficacia de palivizumab en diversos ensayos clínicos Objetivo: Evaluar el hipotético impacto de la

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e36dab6003d782147d3b003a1365a4a8
https://doi.org/10.1157/13051314

Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Autor: Bernal, Teresa^1,2 (AUTHOR) bernalmaria@uniovi.es, Moreno, Ainhoa Fernández^1,2 (AUTHOR), de LaIglesia, Almudena³ (AUTHOR), Benavente, Celina⁴ (AUTHOR), García‐Noblejas, Ana⁵ (AUTHOR), Belmonte, Daniel García⁶ (AUTHOR), Riaza, Rosalía⁷ (AUTHOR), Salamero, Olga⁸ (AUTHOR), Foncillas, Maria Angeles⁹ (AUTHOR), Roldán, Alicia¹⁰ (AUTHOR), Concepción, Víctor Noriega¹¹ (AUTHOR), González, Laura Llorente¹² (AUTHOR), Bergua Burgués, Juan Miguel¹³ (AUTHOR), Lorente de Uña, Soraya¹⁴ (AUTHOR), Rodríguez‐Macías, Gabriela¹⁵ (AUTHOR), de la Fuente Burguera, Adolfo¹⁶ (AUTHOR), García Pérez, Maria José¹⁷ (AUTHOR), López‐Lorenzo, Jose Luis¹⁸ (AUTHOR), Martínez, Pilar¹⁹ (AUTHOR), Aláez, Concepción²⁰ (AUTHOR)

Publikováno v: Cancer Medicine. Jul2023, Vol. 12 Issue 14, p14892-14901. 10p.

Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry.

Autor: Mathur S; Department of Internal Medicine, University of Manitoba, Winnipeg, Canada., Christou G; Division of Hematology, The Ottawa Hospital, Ottawa, Canada., Delage R; Hematology, CHU De Québec-Université Laval, Quebec City, Canada., Elemary M; Hematology, Saskatchewan Cancer Agency, Saskatoon, Canada., Finn N; Hematology, Dr. Georges-L-Dumont University Hospital Centre, Moncton, Canada., Geddes M; Hematology, Tom Baker Cancer Centre, Calgary, Canada., Houston DS; Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.; Department of Medical Oncology & Hematology, Cancer Care Manitoba, Winnipeg, Canada., Keating MM; Division of Hematology, Dalhousie University, Halifax, Canada., Khalaf D; Hematology/Oncology, Juravinski Cancer Centre, Hamilton, Canada., Leber B; Hematology/Oncology, Juravinski Cancer Centre, Hamilton, Canada., Leitch H; Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, Canada., Lother SA; Divisions of Critical Care and Infectious Diseases, University of Manitoba, Winnipeg, Canada., Mozessohn L; Hematology/Oncology, Odette Cancer Center, Toronto, Canada., Nevill T; Hematology, Vancouver General Hospital, Vancouver, Canada., Parmentier A; Hematology/Oncology, Odette Cancer Center, Toronto, Canada., Paulson K; Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.; Department of Medical Oncology & Hematology, Cancer Care Manitoba, Winnipeg, Canada., Rimmer E; Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.; Department of Medical Oncology & Hematology, Cancer Care Manitoba, Winnipeg, Canada., Sabloff M; Division of Hematology, The Ottawa Hospital, Ottawa, Canada.; The Ottawa Hospital Research Institute, Ottawa, Canada., Shamy A; Hematology, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada., St-Hilaire E; Hematology, Dr. Georges-L-Dumont University Hospital Centre, Moncton, Canada., Storring J; Hematology, McGill University Health Centre, Montreal, Canada., Yee K; Hematology, Princess Margaret Cancer Centre, Toronto, Canada., Zhang L; Hematology/Oncology, Odette Cancer Center, Toronto, Canada., Zhu N; Hematology, University of Alberta Hospital, Edmonton, Canada., Hay AE; Hematology, Queen's University, Kingston, Canada., Zarychanski R; Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.; Department of Medical Oncology & Hematology, Cancer Care Manitoba, Winnipeg, Canada., Buckstein R; Hematology/Oncology, Odette Cancer Center, Toronto, Canada., Houston BL; Department of Internal Medicine, University of Manitoba, Winnipeg, Canada. bhouston@cancercare.mb.ca.; Department of Medical Oncology & Hematology, Cancer Care Manitoba, Winnipeg, Canada. bhouston@cancercare.mb.ca.

Publikováno v: Annals of hematology [Ann Hematol] 2024 Nov 22. Date of Electronic Publication: 2024 Nov 22.

Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.

Autor: Okamoto, Haruya, Inoue, Yu, Miyashita, Akihiro, Kawaji-Kanayama, Yuka, Chinen, Shotaro, Fujino, Takahiro, Tsukamoto, Taku, Shimura, Yuji, Mizutani, Shinsuke, Kaneko, Hiroto, Kuwahara-Ota, Saeko, Fuchida, Shin-ichi, Nishiyama, Daichi, Hirakawa, Koichi, Uchiyama, Hitoji, Uoshima, Nobuhiko, Kawata, Eri, Kuroda, Junya

Publikováno v: International Journal of Hematology; Sep2023, Vol. 118 Issue 3, p323-332, 10p